Compare INCR & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INCR | NSPR |
|---|---|---|
| Founded | 1994 | 2005 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.3M | 81.8M |
| IPO Year | N/A | N/A |
| Metric | INCR | NSPR |
|---|---|---|
| Price | $0.95 | $1.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 190.8K | 46.7K |
| Earning Date | 02-15-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $72,158,312.00 | $7,779,000.00 |
| Revenue This Year | $69.54 | $22.76 |
| Revenue Next Year | $41.75 | $75.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.04 |
| 52 Week Low | $0.68 | $1.51 |
| 52 Week High | $1.78 | $3.80 |
| Indicator | INCR | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 35.54 | 33.19 |
| Support Level | $0.90 | $1.51 |
| Resistance Level | $1.08 | $1.95 |
| Average True Range (ATR) | 0.09 | 0.14 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 55.49 | 9.38 |
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.